A platform-agnostic, function first-based antibody discovery strategy using plasmid-free mammalian expression of antibodies

Hybridoma technology has been valuable in the development of therapeutic antibodies. More recently, antigen-specific B-cell selection and display technologies are also gaining importance. A major limitation of these approaches used for antibody discovery is the extensive process of cloning and expre...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ruijun, Prabakaran, Ponraj, Yu, Xiaocong, Mackness, Brian C., Boudanova, Ekaterina, Hopke, Joern, Sancho, Jose, Saleh, Jacqueline, Cho, HyunSuk, Zhang, Ningning, Simonds-Mannes, Helene, Stimple, Samuel D., Hoffmann, Dietmar, Park, Anna, Chowdhury, Partha S., Rao, Sambasiva P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078661/
https://www.ncbi.nlm.nih.gov/pubmed/33899674
http://dx.doi.org/10.1080/19420862.2021.1904546

Ejemplares similares

Ejemplares similares